- Home
- HEPS vs TVTX Comparison
HEPS vs TVTX Comparison
Compare HEPS & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HEPS
- TVTX
- Stock Information
- Founded
- HEPS 2000
- TVTX 2008
- Country
- HEPS Turkey
- TVTX United States
- Employees
- HEPS N/A
- TVTX N/A
- Industry
- HEPS Catalog/Specialty Distribution
- TVTX Biotechnology: Pharmaceutical Preparations
- Sector
- HEPS Consumer Discretionary
- TVTX Health Care
- Exchange
- HEPS Nasdaq
- TVTX Nasdaq
- Market Cap
- HEPS 1.1B
- TVTX 1.3B
- IPO Year
- HEPS 2021
- TVTX N/A
- Fundamental
- Price
- HEPS $2.89
- TVTX $14.92
- Analyst Decision
- HEPS
- TVTX Strong Buy
- Analyst Count
- HEPS 0
- TVTX 13
- Target Price
- HEPS N/A
- TVTX $33.75
- AVG Volume (30 Days)
- HEPS 709.6K
- TVTX 2.0M
- Earning Date
- HEPS 06-12-2025
- TVTX 05-05-2025
- Dividend Yield
- HEPS N/A
- TVTX N/A
- EPS Growth
- HEPS N/A
- TVTX N/A
- EPS
- HEPS N/A
- TVTX N/A
- Revenue
- HEPS $1,167,077,294.00
- TVTX $233,175,000.00
- Revenue This Year
- HEPS $43.21
- TVTX $68.31
- Revenue Next Year
- HEPS $37.58
- TVTX $55.65
- P/E Ratio
- HEPS N/A
- TVTX N/A
- Revenue Growth
- HEPS 82.39
- TVTX 60.55
- 52 Week Low
- HEPS $1.28
- TVTX $5.12
- 52 Week High
- HEPS $4.05
- TVTX $25.29
- Technical
- Relative Strength Index (RSI)
- HEPS 51.06
- TVTX 37.07
- Support Level
- HEPS $2.52
- TVTX $14.13
- Resistance Level
- HEPS $2.82
- TVTX $15.23
- Average True Range (ATR)
- HEPS 0.14
- TVTX 1.31
- MACD
- HEPS 0.03
- TVTX -0.10
- Stochastic Oscillator
- HEPS 96.00
- TVTX 31.70
About HEPS D-Market Electronic Services & Trading
D-MARKET Electronic Services & Trading offers an e-commerce platform in Turkey and the surrounding region. The company is comprised of one reportable segment, namely e-commerce operations. The Group derives revenue from the sales of goods, marketplace revenues, and other revenues.
About TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.